Your browser is no longer supported. Please, upgrade your browser.
ADIL Adial Pharmaceuticals, Inc. daily Stock Chart
Adial Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.87 Insider Own18.60% Shs Outstand6.38M Perf Week25.62%
Market Cap48.49M Forward P/E- EPS next Y-0.88 Insider Trans- Shs Float3.34M Perf Month100.00%
Income-10.80M PEG- EPS next Q-0.18 Inst Own0.30% Short Float8.64% Perf Quarter196.88%
Sales- P/S- EPS this Y-171.20% Inst Trans- Short Ratio0.18 Perf Half Y-
Book/sh0.89 P/B8.54 EPS next Y65.40% ROA-775.40% Target Price5.50 Perf Year-
Cash/sh0.75 P/C10.10 EPS next 5Y- ROE- 52W Range1.11 - 9.44 Perf YTD48.44%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-19.49% Beta-
Dividend %- Quick Ratio16.20 Sales past 5Y- Gross Margin- 52W Low587.47% ATR1.04
Employees3 Current Ratio16.20 Sales Q/Q- Oper. Margin- RSI (14)65.69 Volatility16.61% 22.46%
OptionableNo Debt/Eq0.02 EPS Q/Q- Profit Margin- Rel Volume0.17 Prev Close8.33
ShortableNo LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.64M Price7.60
Recom2.00 SMA2035.94% SMA50120.84% SMA200137.39% Volume277,284 Change-8.76%
Oct-30-18Initiated Maxim Group Buy $5
Oct-11-18Initiated Dawson James Buy
Jan-15-19 09:05AM  Bankole Johnson, MD and Chairman of the Board of Adial Pharmaceuticals Featured in Second Installment of The Doctors Channel Video Series GlobeNewswire +14.58%
Jan-10-19 08:00AM  Adial Pharmaceuticals to Present at The 2019 Wall Street Conference GlobeNewswire +12.07%
Dec-27-18 10:25AM  These 4 Healthcare Stocks Are Gaining Speed ACCESSWIRE -8.40%
Dec-26-18 04:18PM  Why Adial Pharmaceuticals (ADIL) Stock Is Soaring Today InvestorPlace +27.47%
11:57AM  4 Healthcare Stocks Getting A Boost On Wednesday, Dec. 26, 2018 ACCESSWIRE
07:30AM  Biotech News Driving These Companies ACCESSWIRE
Dec-24-18 08:00AM  Adial Pharmaceuticals Retires All Outstanding Debt GlobeNewswire +15.12%
07:30AM  Biotech Breakout Candidates ACCESSWIRE
Dec-20-18 06:50AM  Today's Research Reports on Trending Tickers: Aduro BioTech and Adial Pharmaceuticals ACCESSWIRE -15.66%
Dec-19-18 09:00AM  Adial Pharmaceuticals Announces Amendment to License Agreement with the University of Virginia Licensing & Ventures Group GlobeNewswire +23.39%
Dec-14-18 06:55AM  Today's Research Reports on Trending Tickers: Adial Pharmaceuticals and Cancer Genetics ACCESSWIRE -8.65%
Dec-13-18 12:49PM  Adial Pharmaceuticals News: ADIL Stock Is Skyrocketing Today InvestorPlace +104.93%
08:00AM  Adial Pharmaceuticals Announces Planned Expansion of Lead Asset AD04 into Opioid Addiction Including Synthetic Opioids Such as Fentanyl GlobeNewswire
Dec-10-18 08:00AM  Adial Pharmaceuticals Announces Professor Hannu Alho, Emeritus Professor of Addiction Medicine at the University of Helsinki, Finland as Coordinating Principal Investigator for Phase 3 Clinical Trial of AD04 for the Treatment of Alcohol Use Disorder GlobeNewswire -10.50%
Dec-04-18 06:45AM  Adial Pharmaceuticals, Analysts Coverage, Review and Target ACCESSWIRE
Nov-29-18 10:10AM  Healthcare Stocks Following New Market Trends: Premier Health Group (PHGRF) (PHGI), Alliqua BioMedical, Tonix Pharma, & Adial Pharma ACCESSWIRE +112.12%
09:10AM  Adial Pharmaceuticals Establishes Scientific Advisory Board and Appoints Global Thought Leader in the Field of Alcohol Use Disorder GlobeNewswire
Nov-21-18 08:00AM  Adial Pharmaceuticals Chairman Featured in Doctors Channel Video Discussing Alcohol Use Disorder GlobeNewswire +12.59%
07:25AM  Factors of Influence in 2018, Key Indicators and Opportunity within Atlantic American, Titan Medical, Adial Pharmaceuticals, Aptinyx, Sotherly Hotels, and Titan Pharmaceuticals New Research Emphasizes Economic Growth GlobeNewswire
Nov-19-18 08:00AM  Adial Pharmaceuticals Engages CRO to Begin Phase 3 Clinical Trials of AD04 for the Treatment of Alcohol Use Disorder GlobeNewswire
Nov-14-18 08:00AM  Adial Pharmaceuticals Provides Business Update for the Third Quarter of 2018 GlobeNewswire
Nov-08-18 09:20AM  Addiction Drug Developer Adial Pharmaceuticals Receives Notice of Allowance of Canadian Patent for AD04 in Alcohol Use Disorder GlobeNewswire
Oct-23-18 08:00AM  Adial Pharmaceuticals to Present at Dawson James Securities 4th Annual Small Cap Growth Conference GlobeNewswire +7.88%
Sep-26-18 02:15PM  Adial Pharmaceuticals to Present at The MicroCap Conference on October 1st in New York City ACCESSWIRE
Sep-18-18 07:30AM  Addiction Drug Developer Adial Pharmaceuticals Successfully Passes Patent Opposition Period in Europe for AD04 in Alcohol Use Disorder; Reports No Challenges to European Patent GlobeNewswire +9.59%
Sep-12-18 09:00AM  Alcohol Use Disorder Drug Candidate from Adial Pharmaceuticals Shows Positive Stability Results GlobeNewswire
Sep-04-18 08:00AM  Adial Pharmaceuticals to Ring the Nasdaq Stock Market Opening Bell this Morning at 9:30 AM Eastern GlobeNewswire
Aug-27-18 09:00AM  Leading Addiction Focused Company Adial Pharmaceuticals Comments on Lancet Article Reporting Alcohol is the Number One Cause of Death Globally Among Ages 15 to 49 GlobeNewswire -7.08%
Aug-15-18 08:00AM  Adial Pharmaceuticals Announces Appointment of Monika Rogozinska as Senior Vice President of Drug and Business Development GlobeNewswire
Aug-02-18 05:31PM  Dawson James Securities Announces the Closing of Initial Public Offering of Adial Pharmaceuticals, Inc. GlobeNewswire -5.96%
Jul-31-18 04:05PM  Adial Pharmaceuticals Announces Closing of Initial Public Offering GlobeNewswire
Jul-27-18 07:00AM  Adial Pharmaceuticals Announces Pricing of Initial Public Offering GlobeNewswire
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic agents for the treatment of alcohol use disorders in the United States. Its lead product is AD04, a selective serotonin-3 antagonist that has completed Phase IIb clinical trials for the treatment of nausea and emesis. The company was founded in 2010 and is based in Charlottesville, Virginia.